Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 FY25 Earnings Call

Redempla is approved and launched, but management expects limited fiscal 2026 financial impact from commercial sales.

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2025-11-30
Length67 minutes
EPS$-0.18
Revenue$27.8M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q3 FY26

All ARWR earnings ยท Back to ARWR overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.